US PTAB Patent Cases
8,722 decisions indexed
Page 8 of 291 · 8,722 total
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,554,005 B2 catheter aspiration patent after Imperative Care showed a reasonable likelihood of success on at least one claim. The review covers all 15 claims and four obviousness grounds involving Garrison, Schaffer, Hartley, and Eller references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,974,910 patent after finding Imperative Care likely to succeed on at least one claim, focusing on obviousness over Garrison, Laub, and Aklog references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted an inter partes review of Inari Medical’s hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success on at least one claim.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care successfully instituted an IPR against Inari Medical's 11,969,333 B2 patent covering intravascular clot removal. The Board found a reasonable likelihood of unpatentability based on obviousness over Laub, Garrison, and related references, and instituted review on all 36 challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s hemostasis valve patent after Imperative Care showed a reasonable likelihood of success, focusing on the definition of “filament” and its flexibility versus prior art.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care has filed an IPR petition challenging Inari Medical’s U.S. Patent 12,156,669 covering an endovascular clot‑removal system. The petition asserts anticipation and obviousness over multiple prior‑art references, including Garrison, Goff, Brady, Pons, Schaffer, and Hartley. The Board must decide whether to institute the review.
Meta Platforms, Inc. v.SitNet, LLC
Meta Platforms successfully challenged SitNet’s ’682 patent in an IPR, resulting in all 20 claims being found unpatentable for obviousness over Burfeind and Crowley. The patent owner did not respond, leaving the petition unopposed.
Meta Platforms, Inc. v.SitNet, LLC
Meta Platforms successfully challenged SitNet’s ’932 patent, leading the PTAB to find all ten claims unpatentable as obvious over prior‑art social‑network and advertising systems.
Meta Platforms, Inc. v.SitNet, LLC
Meta Platforms successfully invalidated SitNet’s ’932 patent claims covering targeted advertising in situational networks. The Board found all challenged claims (12‑21) obvious over Amidon, Walsh, Shahine, and Jones. The decision clears Meta’s path for its ad‑tech offerings.
Meta Platforms, Inc. v.SitNet, LLC
Meta Platforms successfully challenged SitNet’s ’682 patent, leading the PTAB to find all 20 claims unpatentable as obvious over prior‑art event‑organization and location‑based systems.
Meta Platforms, Inc. v.SitNet, LLC
Meta Platforms successfully challenged SitNet’s ’682 patent covering situational networks. The PTAB found all 20 claims unpatentable as obvious over prior art references Burfeind and Crowley. The patent owner did not respond, leaving the petitioner’s arguments unopposed.
Meta Platforms, Inc. v.SitNet, LLC
Meta Platforms successfully challenged SitNet’s ’932 patent, leading the PTAB to find all ten claims unpatentable as obvious over Amidon, Walsh, Shahine, and Jones.
Meta Platforms, Inc. v.SitNet, LLC
Meta Platforms petitions the PTAB to invalidate SitNet’s ’815 patent covering social‑network event coordination, asserting that all 30 claims are obvious over existing social‑network and event‑planning technologies.
Meta Platforms, Inc. v.SitNet, LLC
Meta Platforms petitions to invalidate SitNet’s ’769 patent covering situational networks, arguing all 30 claims are obvious over prior art. The petition cites multiple earlier patents and publications and seeks cancellation of the entire patent.
Magnolia Medical Technologies, Inc. v.Kurin, Inc.
Magnolia Medical Technologies petitions the PTAB to invalidate claims 1‑24 of Kurin’s blood‑sample optimization device, asserting that the Bullington800 publication (alone and combined with Brancazio and Liu) anticipates or makes the claims obvious. The petition seeks institution and cancellation of all challenged claims.
Univacco Technology Inc. v.LEONHARD KURZ Stiftung & Co., KG
Univacco Technology Inc. has filed a Post‑Grant Review petition seeking cancellation of 20 claims of the ‘935 decorative‑foil patent, alleging lack of enablement, insufficient written description, and indefiniteness. The petition relies on extensive expert analysis of the patent’s functional language and missing test protocols.
Meta Platforms, Inc. v.SitNet, LLC
Meta Platforms petitions the PTAB to invalidate all twelve claims of SitNet’s U.S. Patent 12,336,052, asserting obviousness over two sets of prior‑art references covering social‑network event handling. The petition seeks cancellation of the entire patent.
Univacco Technology Inc. v.LEONHARD KURZ Stiftung & Co., KG
The PTAB denied institution for PGR2026-00011, finding that the petitioner failed to meet the required standard of likelihood of prevailing or unpatentability.
Samsung Electronics Co., Ltd. et al. v.Massively Broadband LLC
Samsung Electronics petitions the PTAB to invalidate Massively Broadband’s ’925 patent covering a wireless‑network clearinghouse and location‑based advertising, asserting obviousness over multiple prior‑art references.
Ford Motor Company v.AutoConnect Holdings LLC
Ford Motor Company submits an authorized response urging the PTAB to institute its IPR against AutoConnect’s ’186 patent, emphasizing settled expectations from its long‑term Flextronics partnership and AutoConnect’s maintenance‑fee lapses.
Ford Motor Company v.AutoConnect Holdings LLC
Ford Motor Co. faces a PTAB Director Review petition after the Board instituted an IPR on AutoConnect’s infotainment patent. The patent owner argues Ford’s settled‑expectations narrative and claim‑construction positions are inconsistent, warranting discretionary denial of institution.
RJ Brands, LLC d/b/a Chefman v.SharkNinja Operating LLC et al.
RJ Brands (Chefman) has filed an IPR petition challenging SharkNinja’s dual‑air‑fryer patent, arguing lack of priority support and obviousness over four prior‑art references. The petition targets claims 1‑4 and 7‑22 and seeks to have them declared unpatentable.
Apotex Inc. v.Ipsen Biopharm Ltd. et al.
Apotex has filed an IPR petition challenging all 15 claims of Ipsen’s 2017 pancreatic‑cancer treatment patent, arguing the claims are obvious over a body of prior‑art that teaches the same drug regimen.
RJ Brands, LLC d/b/a Chefman v.SharkNinja Operating LLC et al.
RJ Brands has filed an IPR petition challenging SharkNinja’s dual‑air‑fryer patent, arguing lack of priority support and that the claims are anticipated or obvious over Zhang, Conrad, Philips and Moon.
American Airlines, Inc. et al. v.Intellectual Ventures II LLC
American Airlines and Southwest Airlines have filed an IPR petition seeking to invalidate claims 1‑24 of Intellectual Ventures’ LTE‑related patent, alleging obviousness over multiple pre‑grant references. The petition cites Papasakellariou, Classon, Liu, Muharemovic, and Onggosanusi as prior art.
CrowdStrike, Inc. et al. v.Skysong Innovations, LLC
CrowdStrike filed an IPR petition challenging all 18 claims of Skysong Innovations’ ’721 patent, asserting obviousness over a suite of prior‑art references covering browser security, daemons, and DNS techniques. The petition seeks a finding of unpatentability under 35 U.S.C. § 103.
Ford Motor Company v.AutoConnect Holdings LLC
Ford Motor Company has filed an IPR petition challenging AutoConnect’s U.S. Patent No. 9,123,186, which covers vehicle‑access control based on user accounts. The petition asserts that all 21 claims are obvious over earlier automotive restriction systems (Gratz, Bosch, Rector, Moinzadeh). The Board is asked to institute the review.
Apotex Inc. v.Ipsen Biopharm Ltd. et al.
The PTAB granted institution for the IPR involving Apotex Inc. and Ipsen Biopharm Ltd., allowing the merits of the challenge to proceed.
RJ Brands, LLC d/b/a Chefman v.SharkNinja Operating LLC et al.
The USPTO granted institution for IPR2025-01530 and several other proceedings after determining the petitioner had a reasonable likelihood of prevailing. This moves the cases forward to merits review.
RJ Brands, LLC d/b/a Chefman v.SharkNinja Operating LLC et al.
The USPTO granted institution for IPR2025-01529 after determining the petitioner showed a reasonable likelihood of prevailing. This decision is part of a larger set of institutional decisions affecting multiple related proceedings.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.